Home Categories Biochemical Engineering Pomalidomide
BD9542731

Pomalidomide , 98% , 19171-19-8

Synonym(s):
1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline;3-amino-N-(2,6-dioxo-3-piperidyl)phthalamide;4-Amino-2-(2,6-dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione;Actimid;IMiD 3

CAS NO.:19171-19-8

Empirical Formula: C13H11N3O4

Molecular Weight: 273.24

MDL number: MFCD12756407

EINECS: 805-902-5

Pack Size Price Stock Quantity
250mg RMB38.40 In Stock
1g RMB83.20 In Stock
5g RMB236.80 In Stock
10g RMB436.00 In Stock
25g RMB860.80 In Stock
100g RMB2912.80 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 318.5 - 320.5°
Boiling point: 582.9±45.0 °C(Predicted)
Density  1.570±0.06 g/cm3(Predicted)
storage temp.  2-8°C
solubility  DMSO: ≥14mg/mL
pka 10.75±0.40(Predicted)
form  powder
color  yellow
Merck  14,135
Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 1 month.
InChI InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
InChIKey UVSMNLNDYGZFPF-UHFFFAOYSA-N
SMILES C1(=O)C2=C(C(N)=CC=C2)C(=O)N1C1CCC(=O)NC1=O

Description and Uses

In February 2013, the US FDA approved pomalidomide (also known as CC4047) for the treatment of multiple myeloma (MM) in patients with disease progression after receiving other cancer therapeutics. Pomalidomide is a 4-amino analog of thalidomide with enhanced potency and an improved toxicity profile. Pomalidomide and thalidomide exert their effects by modulation of immunity, inhibition of angiogenesis, interference with the bone/tumor microenvironment, and inhibition of the cereblon protein. Pomalidomide potently inhibited in vitro proliferation in a variety of human MM cell lines, IC50~10 nM, while thalidomide showed almost no inhibition up to 100 μM. In mouse MM tumor models, 50 mg/kg daily doses of pomalidomide resulted in marked inhibition of tumor growth after 15 days of treatment and complete regression in 3–6 weeks versus thalidomide-treated controls at the same dose. Pomalidomide is prepared by condensation of 4-nitrophthalic anhydride with 3-aminopiperidine-2,6-dione followed by catalytic hydrogenation of the nitro group.

Pomalidomide inhibits LPS-induced TNF-α release with IC50 of 13 nM

Safety

Symbol(GHS) 
GHS08
Signal word  Danger
Hazard statements  H360D
Precautionary statements  P201-P202-P280-P308+P313-P405-P501
WGK Germany  3
RTECS  NR3397905
HS Code  29251900
Hazardous Substances Data 19171-19-8(Hazardous Substances Data)

RELATED PRODUCTS